康莱特对晚期肺癌患者症状及生活质量的改善作用  

Improvement of Kanglaite on the Symptoms and Quality of Life in Advanced Lung Cancer Patients

作　　者：于涛[1] 张秋生[1] 齐拥军[1] 

机构地区：[1]北京市门头沟区医院,北京102300

出　　处：《中国药业》2015年第23期29-31,共3页China Pharmaceuticals

摘　　要：目的探讨康莱特注射液治疗晚期肺癌患者的症状和生活质量改善情况。方法选择医院2013年6月至2014年12月收治的晚期肺癌患者120例,随机分为观察组和对照组,各60例。对照组给予紫杉醇(25 mg/m^2)+顺铂(135 mg/m^2)方案治疗,观察组在对照组治疗基础上加用康莱特注射液。结果治疗后,观察组患者总有效率为38.33%,症状改善率为76.67%,显著高于对照组的23.33%和48.33%,差异均有统计学意义(P<0.05);观察组卡氏生活质量评分(KPS)和体重改善明显优于对照组(P<0.05);免疫细胞活性明显高于对照组(P<0.05);治疗期间观察组和对照组不良反应情况无显著性差异(P>0.05)。结论康莱特注射液用于晚期肺癌能提高临床疗效,显著改善症状,增强患者免疫力,提高患者生活质量,且不加重不良反应,安全性较高,值得推广。Objective To investigate the clinical efficacy and safety of Kanglaite Injection on patients with advanced lung cancer.Methods 120 cases of patients with advanced lung cancer treated in the hospital from June 2013 to December 2014 were randomly divided into observation group and control group, 60 cases in each group. The control group was given 25 mg / m^2 paclitaxel and135 mg / m^2cisplatin（ TP）,on this basis the observation group was added with Kanglaite Injection. Results After treatment,the total effective rate and the symptom improvement rate of the observation group were 38. 33% and 76. 67%, which were significantly higher than 23. 33% and 48. 33% of the control group（ P 〈 0. 05）; the Karnofsky score and weight improvement of the observation group were significantly higher than that of the control group（ P 〈 0. 05）, and the activity of the immune cells was obviously higher than the control group（ P 〈 0. 05）. The adverse reactions of the two groups had no statistically significant difference（ P 〉 0. 05）.Conclusion Kanglaite Injection can improve the curative effect in the treatment of patients with advanced lung cancer,increase the activity of immune cells,can significantly improve the quality of life of patients,and reduce the incidence rate of adverse reaction during chemotherapy and has high safety,which is worthy of clinical promotion.

关 键 词：康莱特 晚期 肺癌 临床疗效 生活质量 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]